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Abstract 
Vaccine potency testing is conducted to provide manufacturers and regulatory officials information regarding the potency of 
vaccine products prior to market release. Post-licensing potency test protocols are often described and incorporated into 
regulation or guidance documents. This provides manufacturers with a consistent and uniform framework to follow for market 
release. Some of these protocols are based on widely accepted international test methods; others have been in existence for 
decades and were based on the best scientific information available at that time.  
In an effort to ensure that vaccine testing conducted on live animals provides optimal animal welfare, alternative test methods 
incorporating reduction, replacement, and refinement techniques should be considered and used when appropriate. Russell and 
Burch, in The Principles of Humane Experimental Technique, define reduction as “reduction in the numbers of animals used to 
obtain information of a given amount and precision.” This paper will focus on three methods of reducing the number of animals 
used for potency testing. These reduction methods include (1) a change in experimental design, (2) a change based on statistical 
review, and (3) changes resulting from the harmonization of test requirements. 
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1. Introduction 
As a national regulatory authority, the U.S. Department of Agriculture (USDA), Animal and Plant Health 
Inspection Service (APHIS), Center for Veterinary Biologics (CVB) enforces the Virus-Serum-Toxin Act and 
ensures that veterinary vaccines marketed in the United States are pure, safe, potent, and effective [1]. Veterinary 
vaccines are biological products that may be of natural or synthetic origin. They may have been derived by 
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synthesizing or altering various substances or components of substances such as microorganisms, genes or genetic 
sequences, carbohydrates, proteins, antigens, allergens, and antibodies [2]. These are complex substances, and the 
nature of the vaccine manufacturing process introduces a natural degree of variability to each serial of vaccine 
produced. 
Human vaccines also exhibit these characteristics; therefore, regulatory authorities often require each serial of a 
vaccine to be tested prior to market release. Potency testing is conducted to ensure that the vaccine is effective. 
Some of these tests date from the 1940s and 1950s and are based on the “vaccinate and challenge” approach using 
live animals. As these tests proved their reliability through historical results, they were incorporated as standards 
that may be required by a regulatory authority, recommended in a recognized scientific publication, or developed by 
a manufacturer specifically for their product. 
However, there is greater interest today in reviewing the need for live animals for regulatory testing. The 
Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM) Authorization Act 
specifically promotes the consideration of alternative test methods that reduce, refine, or replace animal use while 
still maintaining good science [3]. ICCVAM encourages Federal agencies to share and communicate information 
that facilitates and advances the 3 Rs while ensuring conservation of agency resources. 
Russell and Burch introduced the 3 R principles (reduction, refinement, and replacement) in The Principles of 
Humane Experimental Technique. They define reduction as “reduction in the numbers of animals used to obtain 
information of a given amount and precision” [4]. This paper will provide examples of reduction approaches being 
taken in vaccine potency testing.  
2. Examples 
2.1. Experimental design 
The USDA-codified standard requirement for tuberculin-purified protein derivative (PPD) Bovis, Intradermic 
describes a classic skin test of a type adopted in the 1950s as a replacement for the lethal potency test [2]. The lethal 
potency test dates back to Robert Koch and the late 1800s [5]. Tuberculin-PPD is produced from cultures of 
Mycobacterium bovis that has been inactivated and is nontoxic. This product is used in the USDA Cooperative 
State–Federal Tuberculosis Eradication Program in an effort to eliminate bovine tuberculosis from the livestock 
population. 
The potency test is a standard requirement outlined in Title 9 of the U.S. Code of Federal Regulations, Section 
113.409 [2]. It is further detailed in USDA Supplemental Assay Method 636 [6]. The regulation requires the use of 
adult white female guinea pigs. The test for each serial must include 23 guinea pigs (10 sensitized with M. bovis, 10 
with M. avium, and 3 unsensitized). An additional 20 guinea pigs (10 sensitized with M. bovis and 10 with M. 
avium) are required for the reference tuberculin. 
Each guinea pig is injected intradermally at four sites with different dilutions of either the test serial (23 animals) 
or reference (20 animals). The skin site reactions are measured 24 hours after injection, and satisfactory results are 
based on the difference in average skin reaction response between the M. avium- and M. bovis-sensitized guinea 
pigs. 
A modified tuberculin-PPD test published by the Office International des Epizooties (OIE), also referred to as the 
World Organisation for Animal Health [7], holds promise in reducing the number of animals needed. One version of 
the test uses 15 adult white female guinea pigs. Twelve guinea pigs are sensitized with M. bovis, and three are 
maintained as unsensitized controls. Each animal is injected intradermally at three sites with different dilutions of 
both the test serial (in one area) and reference (in an opposite and parallel site). Satisfactory results in this case are 
based on the degree of similarity in skin reaction response between the test serial and reference.  
This modified test employs a different experimental design than the current standard requirement. The balanced 
incomplete Latin square design, in which each guinea pig is injected with both the test and reference serials, allows 
each animal to act as its own control. This has the advantage of reducing the amount of individual animal variability 
in the test results while maintaining statistical power, even as the number of animals used drops from 43 to 15 per 
potency test. 
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2.2. Statistical review 
The USDA-codified standard requirement for Rabies Vaccine, Killed Virus is outlined in Title 9 of the U.S. Code 
of Federal Regulations, Section 113.209 [2] and further detailed in Supplemental Assay Method 308.03 [8]. It 
incorporates the standard National Institutes of Health (NIH) test for potency as outlined in Chapter 37 of 
Laboratory Techniques in Rabies [9]. This test was developed at the NIH in the mid-1950s and has been included in 
the U.S. requirements for potency testing of both human and veterinary rabies vaccines for decades. Rabies vaccine 
is prepared from inactivated virus-bearing cell cultures or nerve tissues obtained from animals that have developed 
infection following injection with the rabies virus. The veterinary rabies vaccine is used in public health animal 
rabies prevention and control programs. 
The rabies potency test uses adult CF-1 female mice. Five groups of 16 mice each are required for each serial to 
be tested, and five groups of 16 mice each are needed for the reference. An additional four groups of 10 mice each 
are used to establish the dose that kills 50% of the animals tested (LD50) of the challenge virus (a validity 
requirement for the test). 
The test serial and reference groups are vaccinated and challenged two weeks later with an intracerebral 
inoculation of the live virus. The median effective dose (ED50) of the test serial and reference groups are compared, 
and the relative potency is calculated in order to determine if the results are satisfactory. 
Many efforts have been made to establish an alternative test method [10]. One of these is the single-dilution 
assay, as noted by the World Health Organization (WHO) [11]. It is an option that may be used following licensing, 
confirmation of consistency in production and quality control (a Good Manufacturing Practice [GMP] or similar 
environment), and with the approval of the national regulatory authority. As the name implies, this assay uses only 
one group of mice for the test serial, to compare to one group of mice vaccinated with the reference. This could 
reduce the total number of animals needed for the test by two thirds or more. 
The WHO points out that the single-dilution assay provides assurance that the lower limit of the estimated 
potency exceeds the minimum requirement established by the reference. The single-dilution assay produces 
qualitative results but will not provide the quantitative estimates of vaccine potency. Quantitative results may be 
useful in determining the upper limit of the amount of antigen present in order to decrease the possibility of adverse 
reactions (for example, botulinum toxin products) [12]. 
2.3. Global harmonization of test requirements 
International harmonization or mutual recognition of potency test results is a highly desirable approach to 
reducing the overall number of animals used. Veterinary vaccine companies in one country would be able to test 
according to accepted guidelines, and the national authority in the country of importation could accept satisfactory 
results without further testing. 
The USDA is a party to the VICH, the International Cooperation on Harmonisation of Technical Requirements 
for Registration of Veterinary Medicinal Products. The VICH is a trilateral program composed of members from the 
European Union, the U.S., and Japan [13]. Australia, New Zealand, and Canada participate as observers. Members 
include both regulatory authorities and industry representatives. The VICH was established under the auspices of the 
OIE. Countries not involved in the VICH process may still be kept informed of its progress and consulted on draft 
guidelines through the OIE. 
The Target Animal Safety Expert Working Group of the VICH has approved two protocols for target animal 
safety testing of veterinary live and inactivated vaccines. Guideline 41, Examination of Live Veterinary Vaccines in 
Target Animals for Absence of Reversion to Virulence, was approved in 2007 [14]. Guideline 44, Target Animal 
Safety for Veterinary Live and Inactivated Vaccines, was approved in 2008 [15]. These were subsequently adopted 
by the USDA in 2008 and 2010, respectively, as stated in Veterinary Services Memoranda 800.201 [16] and 
800.207 [17]. 
Guidelines 41 and 44 apply to the prelicense testing requirements for veterinary vaccines, that is, those studies 
conducted to support the registration or licensure of a product. These tests are conducted only at this stage and are 
not required routine tests for market release. 
However, an internal concept paper has been developed to consider eliminating the requirements for target 
animal batch (serial) safety testing. Submission of a concept paper to the VICH steering committee is the first step 
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toward developing an international guideline. Target animal batch safety testing is currently required for some 
products prior to market release in order to ensure vaccines are not dangerous or harmful. Eliminating this test will 
require that the safety of these products be demonstrated using other acceptable methods; however, it may reduce 
the number of animals used on an international basis. 
3. Conclusion  
Along with refinement and replacement, reduction is one of the 3 Rs envisioned by Russell and Burch [4]. In 
considering humane test methods, it is a worthy goal to ensure that sound scientific results require only the 
minimum number of animals. As shown in these examples, one must adequately design the experiment, ensure that 
proper statistical analyses are conducted, and encourage broad acceptance of the test method. These efforts will help 
reduce the number of animals used. The examples provided are just a sample of the efforts being made by the 
USDA and others in this area. We must continually review the test methods used, for as science progresses toward 
better understanding of vaccines, we will no doubt hear of more successes in the area of reduction. 
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